Literature DB >> 16980609

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

Delphine Mérino1, Najoua Lalaoui, Alexandre Morizot, Pascal Schneider, Eric Solary, Olivier Micheau.   

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that induces cancer cell death by apoptosis with some selectivity. TRAIL-induced apoptosis is mediated by the transmembrane receptors death receptor 4 (DR4) (also known as TRAIL-R1) and DR5 (TRAIL-R2). TRAIL can also bind decoy receptor 1 (DcR1) (TRAIL-R3) and DcR2 (TRAIL-R4) that fail to induce apoptosis since they lack and have a truncated cytoplasmic death domain, respectively. In addition, DcR1 and DcR2 inhibit DR4- and DR5-mediated, TRAIL-induced apoptosis and we demonstrate here that this occurs through distinct mechanisms. While DcR1 prevents the assembly of the death-inducing signaling complex (DISC) by titrating TRAIL within lipid rafts, DcR2 is corecruited with DR5 within the DISC, where it inhibits initiator caspase activation. In addition, DcR2 prevents DR4 recruitment within the DR5 DISC. The specificity of DcR1- and DcR2-mediated TRAIL inhibition reveals an additional level of complexity for the regulation of TRAIL signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980609      PMCID: PMC1592888          DOI: 10.1128/MCB.00520-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  Characterization of monoclonal antibodies directed against trail or trail receptors.

Authors:  Claudine Vermot-Desroches; Elise Sergent; Brigitte Bonnin; John Wijdenes
Journal:  Cell Immunol       Date:  2005-09-12       Impact factor: 4.868

2.  TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.

Authors:  Roberta Riccioni; Luca Pasquini; Gualtiero Mariani; Ernestina Saulle; Annalisa Rossini; Daniela Diverio; Elvira Pelosi; Antonella Vitale; Anna Chierichini; Michele Cedrone; Robin Foà; Francesco Lo Coco; Cesare Peschle; Ugo Testa
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

3.  Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation.

Authors:  Erika Rimondi; Paola Secchiero; Andrea Quaroni; Carlotta Zerbinati; Silvano Capitani; Giorgio Zauli
Journal:  J Cell Physiol       Date:  2006-03       Impact factor: 6.384

4.  Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.

Authors:  Peter Horak; Dietmar Pils; Griet Haller; Ingrid Pribill; Max Roessler; Sandra Tomek; Reinhard Horvat; Robert Zeillinger; Christoph Zielinski; Michael Krainer
Journal:  Mol Cancer Res       Date:  2005-06       Impact factor: 5.852

5.  Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.

Authors:  P M Chaudhary; M Eby; A Jasmin; A Bookwalter; J Murray; L Hood
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

6.  Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Eugene Varfolomeev; Heather Maecker; Darcie Sharp; David Lawrence; Mark Renz; Domagoj Vucic; Avi Ashkenazi
Journal:  J Biol Chem       Date:  2005-10-15       Impact factor: 5.157

7.  Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.

Authors:  Xiangguo Liu; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

8.  Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.

Authors:  Lauren Clancy; Karen Mruk; Kristina Archer; Melissa Woelfel; Juthathip Mongkolsapaya; Gavin Screaton; Michael J Lenardo; Francis Ka-Ming Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-30       Impact factor: 11.205

9.  Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.

Authors:  M A Degli-Esposti; P J Smolak; H Walczak; J Waugh; C P Huang; R F DuBose; R G Goodwin; C A Smith
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

10.  Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.

Authors:  Ahter D Sanlioglu; Ercument Dirice; Cigdem Aydin; Nuray Erin; Sadi Koksoy; Salih Sanlioglu
Journal:  BMC Cancer       Date:  2005-05-25       Impact factor: 4.430

View more
  102 in total

1.  Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Authors:  Guillaume Jacquemin; Virginie Granci; Anne Sophie Gallouet; Najoua Lalaoui; Aymeric Morlé; Elisabetta Iessi; Alexandre Morizot; Carmen Garrido; Thierry Guillaudeux; Olivier Micheau
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 3.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

Review 4.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

5.  Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency.

Authors:  Julie Mathieu; Wenyu Zhou; Yalan Xing; Henrik Sperber; Amy Ferreccio; Zsuzsa Agoston; Kavitha T Kuppusamy; Randall T Moon; Hannele Ruohola-Baker
Journal:  Cell Stem Cell       Date:  2014-03-20       Impact factor: 24.633

6.  TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Authors:  Johannes Lemke; Andreas Noack; Dieter Adam; Vladimir Tchikov; Uwe Bertsch; Christian Röder; Stefan Schütze; Harald Wajant; Holger Kalthoff; Anna Trauzold
Journal:  J Mol Med (Berl)       Date:  2010-03-31       Impact factor: 4.599

7.  Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.

Authors:  Simon Neumann; Jan Hasenauer; Nadine Pollak; Peter Scheurich
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

Review 8.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

9.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 10.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.